Skip to main content

#Chikungunya virus disease - #Global #situation (#WHO D.O.N., Summary, Oct. 3 '25)

 




Situation at a glance

In 2025, a resurgence of chikungunya virus (CHIKV) disease was noted in a number of countries, including some that had not reported substantial case numbers in recent years. 

Between 1 January and 30 September 2025, a total of 445 271 suspected and confirmed CHIKV disease cases and 155 deaths were reported globally from 40 countries, including autochthonous and travel imported cases. 

Some WHO Regions are experiencing significant increases in case numbers compared to 2024, although others are currently reporting lower case numbers. 

This uneven distribution of cases across regions makes it challenging to characterize the situation as a global rise, however, given the ongoing outbreaks reported globally in 2025, the potential for further spread remains significant

CHIKV disease can be introduced into new areas by infected travelers and local transmission may be established if there is the presence of Aedes mosquito and a susceptible population. 

The risk is heightened by limited population immunity in previously unaffected areas, favorable environmental conditions for vector breeding, gaps in surveillance and diagnostic capacity, and increased human mobility and trade. 

Strengthening disease surveillance, enhancing vector surveillance and control, and improving public health preparedness are essential to mitigate the risk of further transmission. 

Prior to 2025, current or previous autochthonous transmission of CHIKV has been reported from 119 countries and territories. 

A total of 27 countries and territories across six WHO regions have established competent populations of Aedes aegypti mosquitoes but have not yet reported autochthonous CHIKV transmission. 

Additional countries have established populations of Aedes albopictus mosquitoes, which can also transmit CHIKV, and in which transmission efficiency is enhanced for CHIKV lineages with the E1 226V mutation

The presence of these vectors poses a continuous threat of chikungunya introduction and spread in previously unaffected areas. 

Increased CHIKV transmission is driven by multiple factors that include: 

- the expanded geographic distribution of Aedes mosquitoes related to transportation in conveyances and 

- climate change

- unplanned urbanization

- poor water management, and 

- weakened vector surveillance and control. 

CHIKV disease typically causes high population attack rates. In smaller settings such as islands, the transmission dynamics can be temporarily interrupted once a proportion of the population becomes infected and subsequently immune. 

In larger populations however, where enough individuals remain immunologically susceptible, transmission can persist over time, leading to sustained outbreaks

These outbreaks often place a significant burden on healthcare systems due to the number of affected individuals. 

Countries differ in their ability to detect and report chikungunya and other vector-borne diseases, with many outbreaks identified only retrospectively, hindering effective public health responses. 

Early detection of cases, particularly in persons at risk for severe CHIKV disease, and timely access to appropriate medical care are essential for minimizing clinical complications and reducing mortality. 

The variation in distribution of cases across regions highlights the importance of continued investment in surveillance, preparedness, and response capacities to address evolving regional dynamics. 

WHO continues to call on all countries to strengthen their healthcare and laboratory systems to enable rapid detection, timely reporting, and effective response to chikungunya outbreaks.

(...)

Source: World Health Organization, https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON581

____

Comments

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...